

CITATION REPORT

List of articles citing

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

DOI: 10.1016/s0140-6736(14)61059-x
Lancet, The, 2014, 384, 1597-605.

Source: <https://exaly.com/paper-pdf/59285406/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
302	Sofosbuvir as backbone of interferon free treatments. 2014 , 46 Suppl 5, S212-20		19
301	[Treatment of hepatitis C: what is known?]. 2014 , 55, 1419-26		4
300	Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism. 2014 , 6, 870-9		12
299	Hepatitis C beware--the end is nigh. <i>Lancet, The</i> , 2014 , 384, 1557-60	40	18
298	Daclatasvir + asunaprevir: first global approval. 2014 , 74, 1559-71		42
297	[Cost-effective medical therapy of hepatitis C employing novel compensation models - pay for cure]. 2015 , 53, 1414-21		1
296	Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. 2015 , 42, 258-72		36
295	[In Process Citation]. 2015 , 156 Suppl 1, 3-23		1
294	[New era in the treatment of chronic hepatitis C - novel direct acting antivirals]. 2015 , 156, 841-8		
293	[In Process Citation]. 2015 , 156 Suppl 2, 3-24		
292	The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. 2016 , 21, 185-94		5
291	A new era of therapy for hepatitis C virus infection. 2015 , 28, 471-8		16
290	Therapie der Hepatitis C bei Patienten mit Zirrhose sowie vor und nach Lebertransplantation. 2015 , 10, 297-304		
289	Hepatitis C virus drug resistance-associated substitutions: State of the art summary. 2015 , 62, 1623-32		228
288	Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. 2015 , 28, 1011-24		10
287	Progress of antiviral therapy for hepatitis C virus infection. 2015 , 30, 25-33		
286	A case of acute liver dysfunction without elevation of ALT caused by treatment with daclatasvir and asunaprevir. 2015 , 56, 109-112		2

285	Correlation between efficacy of daclatasvir/asunaprevir combination therapy and HCV NS3/NS5A resistance-associated variants detected by the PCR-Invader assay. 2015 , 56, 113-115	
284	Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. 2015 , 22, 861-70	64
283	Recent advances in management of the HIV/HCV coinfecting patient. 2015 , 10, 981-997	4
282	Recommendations for treatment of hepatitis C. Polish Group of HCV Experts - 2015. 2015 , 1, 97-104	3
281	Hepatitis C virus: Virology, diagnosis and treatment. 2015 , 7, 1377-89	82
280	Interferon-free combination therapies for the treatment of hepatitis C: current insights. 2015 , 7, 51-70	46
279	Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections. 2015 , 10, e0125846	14
278	Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. 2015 , 10, e0134395	64
277	Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy. 2015 , 10, e0138060	18
276	Successes and Challenges on the Road to Cure Hepatitis C. 2015 , 11, e1004854	30
275	[New Therapeutic Agent for Chronic Hepatitis C: Direct Acting Agent]. 2015 , 66, 5-9	1
274	Hepatitis C treatment in patients on the liver transplant waiting list. 2015 , 20, 242-50	4
273	Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. 2015 , 7, 11-20	2
272	Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone. 2015 , 59, 5503-10	25
271	Optimal management of patients with chronic hepatitis C and comorbidities. 2015 , 35 Suppl 1, 35-43	10
270	Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in. 2015 , 21, 423-34	21
269	Hepatitis C. <i>Lancet, The</i> , 2015 , 385, 1124-35	40 365
268	Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories. 2015 , 59, 2496-507	40

267	Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma. 2015 , 107, 409-18	48
266	Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor. 2015 , 104, 2813-23	23
265	Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. 2015 , 61, 1523-32	69
264	Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir. 2015 , 61, 400-1	31
263	In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir. 2014 , 4, 137	18
262	Sustained Virological Response and Hepatitis C-Related Cirrhosis: a World of Opportunities. 2015 , 14, 32-39	
261	The New Era of Interferon-Free Treatment of Chronic Hepatitis C. 2015 , 31, 290-6	14
260	Management of HCV in the liver transplant setting. 2015 , 39 Suppl 1, S115-9	5
259	Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions. 2015 , 54, 1205-22	37
258	Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. 2015 , 373, 714-25	337
257	Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. 2015 , 149, 971-80.e1	67
256	Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. 2015 , 4, 593-605	4
255	Hepatitis C and HIV Coinfection for Social Workers in Public Health, Medical and Substance Use Treatment Settings. 2015 , 30, 325-35	2
254	Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. 2015 , 9, 547-58	19
253	Hepatitis C und Nierentransplantation. 2015 , 10, 107-112	0
252	High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study. 2015 , 61, 817-25	12
251	The ongoing debate of who to treat for chronic hepatitis C virus. 2015 , 175, 169-70	6
250	Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. 2015 , 313, 1736-44	103

249	Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. 2015 , 9, 486-507	13
248	Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy. 2015 , 75, 823-34	12
247	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. 2015 , 62, 79-86	207
246	HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. 2015 , 9, 424-30	29
245	Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. 2015 , 63, 554-63	20
244	Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice. 2015 , 50, 1145-51	26
243	[Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA]. 2015 , 53, 139-42	
242	Editorial Commentary: Who is "Special" Now?. 2015 , 61, 826-8	
241	Asunaprevir for hepatitis C: a safety evaluation. 2015 , 14, 1631-46	6
240	High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms. 2015 , 32, 637-49	63
239	Hepatitis C: An Eastern Perspective. 2015 , 44, 793-805	3
238	Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. 2015 , 33, 613-23	13
237	Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. 2015 , 35, 2358-62	14
236	[S3 guideline hepatitis C addendum]. 2015 , 53, 320-34	37
235	Asunaprevir (BMS-650032) for the treatment of hepatitis C virus. 2015 , 13, 1307-17	4
234	Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma. 2015 , 44, 761-73	12
233	Alcoholic liver disease: Clinical and translational research. 2015 , 99, 596-610	28
232	High-resolution genetic profile of viral genomes: why it matters. 2015 , 14, 62-70	10

231	Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain. 2015 , 34, 2247-55		5
230	Trends and risk factors for HIV, HCV and syphilis seroconversion among drug users in a methadone maintenance treatment programme in China: a 7-year retrospective cohort study. 2015 , 5, e008162		23
229	The safety of daclatasvir for the treatment of hepatitis C. 2015 , 14, 1787-97		2
228	Daclatasvir for the treatment of chronic hepatitis C. 2015 , 16, 2679-88		6
227	Emerging treatments for chronic hepatitis C. 2015 , 114, 204-15		32
226	New kids on the block--step by step to an ideal HCV therapy. <i>Lancet, The</i> , 2015 , 385, 1050-2	40	9
225	Direct Acting Antivirals Which Is Effective in Pan-genotypic Chronic Hepatitis C Patients with or without Liver Cirrhosis. 2016 , 68, 229		
224	[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1]. 2016 , 67, 127-31		1
223	Anti-Hepatitis Virus Agents. 2016 , 239-270		
222	Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview. 2016 , 4, 336-344		4
221	Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts - 2016. 2016 , 2, 27-33		13
220	Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir. 2016 , 10, 352-9		2
219	Recent Advances in Antiviral Therapy for Chronic Hepatitis C. 2016 , 2016, 6841628		39
218	Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. 2016 , 13, 418-23		23
217	Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. <i>Viruses</i> , 2016 , 8, 91	6.2	16
216	Hepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress Response. <i>Viruses</i> , 2016 , 8,	6.2	54
215	Management of direct antiviral agent failures. 2016 , 22, 432-438		30
214	Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. 2016 , 46, 423-33		22

213	Hepatitis C virus resistance to the new direct-acting antivirals. 2016 , 12, 1197-209	36
212	Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. 2016 , 36, 635-643	7
211	Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. 2016 , 36, 954-62	13
210	Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. 2016 , 43, 1276-92	103
209	Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin. 2016 , 22, 692-9	5
208	All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. 2016 , 36, 1433-41	24
207	miRNA antagonism and direct-acting antivirals: could this be a novel combination treatment against HCV?. 2016 , 11, 753-756	1
206	Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. 2016 , 63, 63-73	37
205	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. 2016 , 10, 681-701	60
204	Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy. 2016 , 9, 89-92	2
203	JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. 2016 , 46, 129-65	48
202	Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. 2016 , 151, 70-86	402
201	Prevention and management of treatment failure to new oral hepatitis C drugs. 2016 , 17, 1215-23	42
200	APASL consensus statements and recommendation on treatment of hepatitis C. 2016 , 10, 702-26	155
199	Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. 2016 , 13, 338-51	122
198	Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. 2016 , 41, 478-85	20
197	Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients. 2016 , 31, 14-22	42
196	A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. 2016 , 31, 1860-1867	28

195	Hepatitis C virus: how to provide the best treatment with what I have. 2016 , 36 Suppl 1, 58-61	3
194	New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). 2016 , 15, 85-100	15
193	Future landscape of hepatitis C research - Basic, translational and clinical perspectives. 2016 , 65, S143-S155	23
192	Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. 2016 , 71, 3495-3505	19
191	Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. 2016 , 26, 408-434	32
190	Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents. 2016 , 6, 34652	20
189	Host Genetics and Responses to Antiviral Therapy in Chronic Hepatitis C. 2016 , 225-241	
188	Hepatitis C Virus II. 2016 ,	1
187	A case of rhabdomyolysis associated with combined administration of daclatasvir and asunaprevir for the treatment of chronic hepatitis C. 2016 , 57, 598-605	1
186	A case of hepatitis C related cirrhosis with genotype 1b relapsed after combination therapy with Sofosbuvir and Ledipasvir. 2016 , 57, 391-396	1
185	Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. 2016 , 355, i5078	53
184	Approved Antiviral Drugs over the Past 50 Years. 2016 , 29, 695-747	73 ¹
183	Hepatitis C virus treatment update I A new era of all-oral HCV treatment. 2016 , 3, 153-160	10
182	Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir. 2016 , 33, 1169-79	20
181	Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. 2016 , 22, 846-852	23
180	Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. 2016 , 151, 501-512.e1	169
179	Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir. 2016 , 60, 1106-13	37
178	Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. 2016 , 43, 674-96	107

177	Daclatasvir in hepatitis C virus infection: a guide to its use in the EU. 2016 , 32, 42-49	3
176	How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?. 2016 , 62, 919-926	61
175	Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. 2016 , 10, 258-66	7
174	Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment. 2016 , 213, 216-23	117
173	High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. 2016 , 10, 310-9	47
172	Characteristics and health of homeless families: the ENFAMS survey in the Paris region, France 2013. 2016 , 26, 71-6	40
171	Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. 2016 , 12, 353-61	13
170	Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. 2016 , 25, 557-72	16
169	Ideal oral combinations to eradicate HCV: The role of ribavirin. 2016 , 64, 215-25	34
168	The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. 2016 , 64, 486-504	337
167	Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection. 2016 , 50, 39-46	41
166	NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection. 2016 , 213, 206-15	30
165	Clinical features and prognosis of elderly patients with hepatocellular carcinoma not indicated for surgical resection. 2017 , 17, 189-201	18
164	Efficacy and safety of telaprevir with pegylated interferon α 2a and ribavirin in Japanese patients. 2017 , 47, 514-521	4
163	Safety and efficacy of faldaprevir in combination with pegylated interferon α 2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection. 2017 , 47, E142-E151	
162	Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis. 2017 , 47, E120-E131	29
161	Chronic hepatitis C and chronic kidney disease: Advances, limitations and uncharted territories. 2017 , 24, 442-453	26
160	Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up. 2017 , 21, 764-770	1

159	Management of hepatitis C virus infection in the Asia-Pacific region: an update. 2017 , 2, 52-62	43
158	Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. 2017 , 7, 41660	19
157	Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. 2017 , 32, 1436-1442	26
156	Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease. 2017 , 37, 1304-1313	3
155	Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. 2017 , 47, 1165-1173	12
154	Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. 2017 , 32, 1754-1762	51
153	New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir. 2017 , 52, 855-867	9
152	Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. 2017 , 37, 635-646	17
151	Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing. 2017 , 7, 45605	12
150	Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1. 2017 , 32, 1998-2005	14
149	Protease Inhibitor Resistance. 2017 , 21-40	
148	Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation. 2017 , 47, 1147-1154	2
147	The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir. 2017 , 11, 103-113	5
146	Urgency to treat patients with chronic hepatitis C in Asia. 2017 , 32, 966-974	18
145	A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. 2017 , 139, 18-24	3
144	NS5A inhibitors for the treatment of hepatitis C infection. 2017 , 24, 180-186	20
143	Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir. 2018 , 23, 53-66	20
142	Direct-acting antivirals for chronic hepatitis C. 2017 , 9, CD012143	38

141	Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience. 2017 , 31, e13109	9
140	Resistance to hepatitis C virus. Implications and therapeutic options. 2017 , 40, 484-494	
139	Resistance to hepatitis C virus. Implications and therapeutic options. 2017 , 40, 484-494	1
138	Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. 2017 , 96, e5321	5
137	Direct-acting antivirals for chronic hepatitis C. 2017 , 6, CD012143	33
136	Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. 2017 , 7, e013620	23
135	Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients. 2017 , 89, 1963-1972	10
134	Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. 2018 , 23, 229-238	43
133	Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir. 2017 , 10, 41-46	3
132	Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. 2017 , 52, 385-395	38
131	Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. 2017 , 32, 45-52	16
130	Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis. 2017 , 52, 26-38	48
129	Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. 2017 , 52, 504-511	14
128	Asunaprevir Evokes Hepatocytes Innate Immunity to Restrict the Replication of Hepatitis C and Dengue Virus. 2017 , 8, 668	3
127	Recommendations for the treatment of hepatitis C in 2017. 2017 , 3, 47-55	24
126	Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients. 2017 , 2017, 9849823	11
125	CONTEXTUALIZAÇÃO E AVANÇOS NO TRATAMENTO DA HEPATITE C: UMA REVISÃO DA LITERATURA. 2017 , 18,	1
124	Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir+Asunaprevir therapy in Korean patients with genotype 1b hepatitis C. 2017 , 14, 164	3

123	Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies. 2017 , 4, ofx095	12
122	Resistance to Direct-Acting Antiviral Agents in Treatment of Hepatitis C Virus Infections. 2017 ,	
121	▣ Daclatasvir plus asunaprevir dual therapy for chronic HCV genotype 1b infection: results of Turkish early access program. 2017 , 16, 71-76	0
120	Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection. 2018 , 53, 1089-1097	1
119	Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. 2018 , 37, 17-39	122
118	Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review. 2018 , 13, 775-790	2
117	Using -Butyl Groups in a Ligand To Identify Its Binding Site on a Protein. 2018 , 9, 109-113	4
116	Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. 2018 , 47, 550-562	43
115	Assessing Racial Disparities in HCV Infection and Care Outcomes in a Southern Urban Population. 2018 , 5, 1052-1058	2
114	Treatment of hepatitis C in special populations. 2018 , 53, 591-605	20
113	Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. 2018 , 7, 261-275	4
112	Protease inhibitor therapy for hepatitis C virus-infection. 2018 , 19, 577-587	32
111	Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. 2018 , 117, 518-526	11
110	Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. 2018 , 38, 821-833	17
109	Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir. 2018 , 25, 126-133	4
108	Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C. 2018 , 39, 140-153	1
107	Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. 2018 , 90, 907-918	13
106	Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b. 2018 , 48, 255-263	2

105	2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. 2018 , 24, 169-229	24
104	Interferon-Free Regimen for Hepatitis C: Insight and Management. 2018 , 28, 373-384	
103	The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study. 2018 , 72, 197-204	
102	Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection. 2018 , 58, 1479-1488	2
101	Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance. 2018 , 23, 705-708	3
100	Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era. 2018 , 285, 55-71	8
99	Natural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolates. 2018 , 15, 144	4
98	Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China. 2018 , 38, 1031-1039	8
97	The Mexican consensus on the treatment of hepatitis C. 2018 , 83, 275-324	9
96	[Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012]. 2018 , 56, 756-838	24
95	Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan. 2018 , 12, 244-253	8
94	Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy. 2018 , 10, 33-42	3
93	The Mexican consensus on the treatment of hepatitis C. 2018 , 83, 275-324	
92	Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. 2018 , 46, 761-783	15
91	Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. 2018 , 14, 649-657	3
90	Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection. 2018 , 27, 797-805	2
89	Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. 2019 , 34, 364-369	20
88	A case with acute-on-chronic liver failure receiving liver transplantation during daclatasvir and asunaprevir therapy in chronic hepatitis C patient. 2019 , 7, 371-373	1

87	Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C. 2019 , 14, e0219022	2
86	Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina. 2019 , 91, 1970-1978	5
85	World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents. 2021 , 19, 1906-1914.e25	6
84	Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test. 2019 , 91, 2158-2165	0
83	Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study. 2019 , 118, 1014-1023	7
82	Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea. 2019 , 91, 1104-1111	2
81	Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection. 2019 , 25, 944-950	10
80	Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the Potency of Direct-Acting Antiviral Agents. 2019 , 63,	8
79	Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures. 2019 , 39, 354-368	21
78	Hepatocellular carcinoma after direct-acting antiviral drug treatment in patients with hepatitis C virus. 2019 , 3, 52-60	9
77	Viral hepatitis C treatment shortening - what is the limit?. 2019 , 5, 265-270	3
76	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. 2019 , 118, 556-564	8
75	Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study. 2019 , 49, 125-135	11
74	Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States. 2019 , 53, 40-50	9
73	Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure. 2020 , 50, 303-312	5
72	Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. 2020 , 58, 1110-1131	3
71	Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China. 2020 , 10, e035224	5
70	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. 2020 , 119, 1019-1040	27

69	Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection. 2020 , 15, e0234811	0
68	Single-molecular real-time deep sequencing reveals the dynamics of multi-drug resistant haplotypes and structural variations in the hepatitis C virus genome. 2020 , 10, 2651	6
67	Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. 2021 , 66, 1315-1326	5
66	Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems. 2021 , 36, 1152-1158	4
65	Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis. 2021 , 36, 601-608	8
64	Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial. 2021 , 36, 2375-2382	2
63	Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals. 2021 , 77, 88-91	0
62	HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies. 2016 , 257-285	1
61	Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. 2017 , 553-627	0
60	Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients. 2020 , 99, e21898	3
59	Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus. 2016 , 4, 88-93	7
58	Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay. 2015 , 10, e0130022	28
57	Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile. 2015 , 10, e0141660	11
56	Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b. 2016 , 11, e0151238	4
55	Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. 2016 , 11, e0155142	8
54	Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. 2016 , 11, e0163884	6
53	Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients. 2016 , 11, e0165658	8
52	Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: a meta-analysis of randomized trials. 2015 , 107, 591-7	5

51	Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions. 2016 , 55, 3595-3601	5
50	Eradication of hepatitis C virus in patient with cryoglobulinemic vasculitis and mutations D168E, L31V. 2020 , 12, 104-110	1
49	Protease inhibitors for the treatment of hepatitis C virus infection. 2017 , 5, Doc08	11
48	Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection. 2016 , 22, 259-66	7
47	Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype 1b infection: a retrospective multi-institutional study. 2017 , 23, 51-56	12
46	KASL clinical practice guidelines: management of hepatitis C. 2016 , 22, 76-139	58
45	Hepatitis C: New challenges in liver transplantation. 2015 , 21, 5768-77	2
44	Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. 2016 , 22, 3418-31	11
43	Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. 2018 , 24, 1361-1372	5
42	Exploring the hepatitis C virus genome using single molecule real-time sequencing. 2019 , 25, 4661-4672	9
41	A 2015 roadmap for the management of hepatitis C virus infections in Asia. 2015 , 30, 423-33	17
40	Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world. 2019 , 34, 794-801	3
39	Treatment of Chronic Hepatitis C Using Newly Developed Oral Antiviral Agents. 2015 , 88, 635	1
38	Updated Treatment of Chronic Hepatitis C. 2017 , 92, 24-35	6
37	The new era of hepatitis C virus therapy. 2015 , 21, 345-54	2
36	Update on hepatitis C: Direct-acting antivirals. 2015 , 7, 2829-33	18
35	Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. 2015 , 7, 725-37	42
34	Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. 2015 , 7, 1133-41	18

33	Limitations and opportunities of non-invasive liver stiffness measurement in children. 2017 , 9, 409-417	6
32	Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. 2017 , 11, 335-348	12
31	The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients. 2018 , 12, 86-93	5
30	Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. 2018 , 12, 324-330	6
29	Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis. 2016 , 16, e41077	13
28	Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience. 2018 , 18,	2
27	The Role of RASs /RVs in the Current Management of HCV. <i>Viruses</i> , 2021 , 13,	6.2 2
26	Two Types of Viral Hepatitis, Two Different Treats from Pharma -What's After the Liver Meeting? 2014?. 2015 , 2,	
25	Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. 2015 , 3, 1005-10	
24	Protease Inhibitor Resistance. 2015 , 1-17	
23	Daclatasvir. 2015 , 38, 217-9	1
22	Asunaprevir. 2016 , 39, 58-60	
21	Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System. 2016 , 4, 5-11	
20	Is stronger better in curing hepatitis C virus infection?. 2016 , 4, 386	
19	Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. 2016 , 4, 320-327	14
18	HCV Drug Resistance. 2017 , 579-609	
17	Biomarkers in Focus: Alanine Aminotransferase. 2017 , 267-280	1
16	Treatment of Hepatitis C. 2018 , 446-463.e3	

- 15 Liver Stiffness Measurement Is Useful to Predict Early Recurrence of Hepatocellular Carcinoma after Sustained Virological Responses by Direct Antiviral Agents in Patients with Hepatitis C. **2018**, 08, 255-268
- 14 GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo. **2018**, 39, 1746-1752 1
- 13 Efficacy and Safety of Daclatasvir and Asunaprevir Combination Therapy in Elderly Chronic Hepatitis C Patients. **2018**, 35, 453-462
- 12 Organization of medical care and drug provision for patients with chronic hepatitis C in Moscow. **2019**, 8, 84
- 11 Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study. **2019**, 34, e264 0
- 10 Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea. **2019**, 13, 549-556 1
- 9 [Antiviral therapy of chronic hepatitis C: 30 years success story]. **2019**, 91, 110-115 1
- 8 ERKRANKUNGEN DER VERDAUUNGSORGANE. **2020**, pA-1-pA7.8-14
- 7 Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants. **2021**, 10, 0
- 6 Effects of Hepatitis C Virus Elimination by Direct-Acting Antiviral Agents on the Occurrence of Oral Lichen Planus and Periodontal Pathogen Load: A Preliminary Report. **2021**, 2021, 8925879
- 5 Efficacy and Safety of Direct-Acting Antiviral Therapy for Hepatitis C Virus in Elderly Patients (≥65 years old): A Systematic Review and Meta-Analysis.. **2022**,
- 4 To go or not to go? Biological logic gating engineered T cells.. **2022**, 10, 0
- 3 Breakthroughs in hepatitis C research: from discovery to cure. 5
- 2 Direct-Acting Antiviral Agents for Hepatitis C Virus InfectionFrom Drug Discovery to Successful Implementation in Clinical Practice. *Viruses*, **2022**, 14, 1325 6.2 2
- 1 Daclatasvir, an Antiviral Drug, Downregulates Tribbles 2 Pseudokinase and Resensitizes Enzalutamide-Resistant Prostate Cancer Cells. **2023**, 22, 381-392 0